Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
Go back to Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026| (NASDAQ: KURA) | Delayed: 10.34 -0.11 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.45 | 52 Week High | $8.90 | |||
| Open | $10.47 | 52 Week Low | $2.50 | |||
| Day High | $10.57 | P/E | N/A | |||
| Day Low | $10.21 | EPS | $0.00 | |||
| Volume | 680,887 | |||||
